PeptideStack
5.2kquestions
20kanswers
220users

What did REDEFINE-1 do with participants who could not tolerate a step?

Asked 9 Aug 2024Modified 2.0 years agoViewed 29k times
27

The label documentation for the agent in question is ambiguous on exactly this point.

The figures are clear enough; the question is what they mean and what they do not.

I can supply the numbers if the specifics change the answer.

How should I read this, and where are the traps?

titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

444 questionsclinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

913 questionsgi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

416 questions
shareeditfollowflag
FB
askedfresh_bac13k289 Aug 2024
7Confirming from the other direction: I did the wrong thing and got exactly the predicted outcome. – b_delacroix 5 months ago
6Is there a reason to prefer the second method over the first, other than cost? – tandem_gradient 3 months ago
add a comment

No answers yet

This question has not been answered. It has been viewed 29k times, which suggests the question is of interest and the answer is not obvious. If you can answer it with a source or a worked calculation, it will be read. See how to ask and answer.
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.